Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Nikhil Vad"'
Autor:
Felix Chu, Michael Harbell, Amy Manning-Bog, Alexander Scholz, Ngan Nguyen, Norman Greenberg, William Robinson, Daniel Emerling, Tito Serafini, Wei Cao, Yvonne Leung, Nikhil Vad, Anne Ye, Daniel Santos, Cathrin Czupalla, John Vivian, Carlene Williams, Judevin Sapugay, Shaun Lippow, Chantia Carroll, Lance Kates, Benjamin Haugen, Gary Bolton, Mark Armanini, Iraz Aydin, Mark Whidden, Mauricio Velasco-Delgado, Erin Wechsler
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/d68b61ac36ac49e5b4d60c03de821131
Autor:
Maryam Bhatti, Michael Weiss, Amanda Haltom, Jessica Finn, Annie Gai, Anne Ye, Danhui Zhang, Cathrin Czupalla, Andreea Stuparu, Yvonne Leung, Erin Wechsler, Iraz Aydin, Daniel Emerling, Amy Manning-Bog, Nikhil Vad, Alexander Scholz, Philippe Marguet, Shaun Lippow
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Alexander Scholz, Jeff DeFalco, Yvonne Leung, Iraz T. Aydin, Cathrin J. Czupalla, Wei Cao, Daniel Santos, Nikhil Vad, Shaun M. Lippow, Gilson Baia, Michael Harbell, Judevin Sapugay, Danhui Zhang, Dai-Chen Wu, Erin Wechsler, Anne Z. Ye, Jenny W. Wu, Xiao Peng, John Vivian, Hargita Kaplan, Rodney Collins, Ngan Nguyen, Mark Whidden, Dongkyoon Kim, Carl Millward, Jonathan Benjamin, Norman M. Greenberg, Tito A. Serafini, Daniel E. Emerling, Lawrence Steinman, William H. Robinson, Amy Manning-Bog
Publikováno v:
Proceedings of the National Academy of Sciences. 119
Immunotherapy approaches focusing on T cells have provided breakthroughs in treating solid tumors. However, there remains an opportunity to drive anticancer immune responses via other cell types, particularly myeloid cells. ATRC-101 was identified vi
Autor:
Norman M. Greenberg, Chantia Carroll, Daniel Emerling, Cathrin J. Czupalla, Iraz T Aydin, Felix Chu, Benjamin Haugen, Shaun M. Lippow, Alexander Scholz, Ngan Nguyen, Nikhil Vad, Yvonne Leung, William H. Robinson, Wei Cao, Lance Kates, Mark Whidden, Gary Bolton, Mark Armanini, Amy Manning-Bog, Tito Serafini, John Vivian, Judevin Lugar Sapugay, Anne Ye, Daniel Santos, Carlene Williams, Michael Harbell, Erin Wechsler, Mauricio Velasco-Delgado
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background We have previously demonstrated adaptive antibody responses targeting public tumor antigens in cancer patients. ATRC-101, a clinical stage, engineered version of an antibody identified in such a patient, displays robust single-agent activi
Autor:
Jeff DeFalco, Ish Dhawan, Carl Millward, Daniel Emerling, Felix Chu, Iraz T Aydin, Shaun M. Lippow, Jonathan Benjamin, Michael Harbell, Cathrin J. Czupalla, Gilson Baia, Mark Whidden, Anne Ye, Amy Manning-Bog, Mauricio Velasco-Delgado, Dai-Chen Wu, John Vivian, Norman M. Greenberg, Yvonne Leung, Tito Serafini, Alexander Scholz, Nikhil Vad, Judevin Lugar-Supagay, Ngan Nguyen, William H. Robinson
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background We have previously described ATRC-101, a fully human, engineered IgG1 antibody binding a tumor-restricted ribonucleoprotein (RNP) complex as its target. ATRC-101 is currently under evaluation in the clinic as a monotherapy for solid tumors
Publikováno v:
Journal for ImmunoTherapy of Cancer. 9:A588-A588
BackgroundWe previously described ATRC-101, a fully human, engineered IgG1 antibody which is currently under evaluation in the clinic as a monotherapy for solid tumors. A chimeric version of this antibody expressed on a mouse IgG2a (mATRC-101) has sh
Autor:
Mohamed A. Y. Abdel-Malek, Nikhil Vad, Sajjeev Jagannathan, Ehsan Malek, James J. Driscoll, Anil G. Jegga, KC Anderson, Pieter Sonneveld, Rebekah Karns, Annemiek Broyl, Francesca Cottini, M. van Duin
Publikováno v:
Leukemia, 31(3), 645-653. Nature Publishing Group
Leukemia
Leukemia
While clinical benefit of the proteasome inhibitor (PI) bortezomib (BTZ) for multiple myeloma (MM) patients remains unchallenged, dose-limiting toxicities and drug resistance limit the long-term utility. The E3 ubiquitin ligase Skp1–Cullin-1–Skp2
Publikováno v:
Tumor Biology. 35:4967-4976
Several epidemiological studies show that aspirin can act as a chemopreventive agent and decrease the incidences of various cancers including melanoma. In this work, we investigated the in vitro and in vivo efficacy of acetylsalicylic acid (ASA) as a
Autor:
Nikhil Vad, Majid Y. Moridani, Shashi K. Kudugunti, Amanda J. Whiteside, Kalkunte S. Srivenugopal, Mohd Aslam Yusuf, Bhakti U. Naik
Publikováno v:
Chemico-Biological Interactions. 188:1-14
In the current work, we investigated the in vitro biochemical mechanism of Caffeic Acid Phenylethyl Ester (CAPE) toxicity and eight hydroxycinnamic/caffeic acid derivatives in vitro, using tyrosinase enzyme as a molecular target in human SK-MEL-28 me
Autor:
C. Patrick Reynolds, Dong Wang, Nikhil Vad, Dattesh U. Verlekar, Charlie Linch, Barry James Maurer, Min H. Kang, Hwangeui Cho
Publikováno v:
Cancer Research. 78:2885-2885
Introduction: We have reported that fenretinide (4-HPR) is active against high-risk neuroblastoma (NB) in vitro and in vivo; our Phase I trials of novel 4-HPR formulations evidenced clinical activity. Mechanisms of activity include increase of cytoto